Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cancer Stem Cell Differentiation In Reverse, Spontaneously

This article was originally published in Start Up

Executive Summary

Scientists have now shown that both normal and cancerous mammary cells may spontaneously "de-differentiate" into stem cells without any genetic manipulations. This apparently innate cellular plasticity suggests new possibilities for utilizing cultured cells both as a tool in the discovery of cancer therapies that target cancer stem cells and also as an autologous therapy in regenerative medicine.

You may also be interested in...

The Hype And Hope Of Cancer Stem Cell Therapeutics

A wave of recent deals demonstrates a growing belief in the potential cancer stem cells might offer for more effective cancer therapies. Some say there’s more hope and hype than science behind the activity. As the science unfolds, fundamental questions have yet to be answered about the pathway to products, especially as drug developers train their lines of sight on solid tumors.

Evidence Of Lung Stem Cells In Adults

Whether a range of organ-specific stem cells exists and can be harnessed for potential therapy is an open question, but encouragingly, researchers have now provided evidence of human lung-specific stem cells. In addition to their potential role in regenerative medicine of the lung, continuing research around the methods used to find these cells could be a starting point for the development of improved methods for identifying enriched or more potent organ-specific stem cell populations.

Stem Cells: What's the Business Model?

The science of stem cells is progressing, slowly but surely, towards the ultimate goal of creating a therapeutic. The challenge is now largely economic: convincing investors that stem cells present a viable business opportunity.

Related Content


Related Companies

Related Deals

Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts